XBiotech Director Purchased 368,524 Shares for $711,251
John Simard bought the shares at $1.93 each and directly owned 4,191,690 shares after the transaction.
Related stories
Analysts Raise Price Targets for ICON After Q3 Earnings
Deutsche Bank raised its ICON target to $250 from $200, RBC to $226 from $185, and Truist Securities to $268 from $209. All three firms maintained their existing Buy or Outperform
M impact | EQUITY | Oct 29, 2026, 02:03 PM UTC
Baldwin Group Reports 8% Fall in Commercial Property Insurance Pricing
Commercial property insurance pricing fell 8% in Q3 2026, Baldwin Group reported.
M impact | EQUITY | Oct 29, 2026, 02:03 PM UTC
Restaurant Brands Executive Sees Some Impact From Higher Gas Prices
A Restaurant Brands executive said higher gasoline prices are having some impact, especially in drive-thru and rural markets.
M impact | EQUITY | Oct 29, 2026, 02:02 PM UTC
José Cuervo Shares Resume Trading After Brief Suspension, Down Nearly 14%
Shares resumed trading after a brief suspension and remained down nearly 14%.
M impact | EQUITY | Oct 29, 2026, 02:02 PM UTC
CRH Cuts FY26 Outlook and Authorizes Up to $6 Billion Buyback
CRH lowered its 2026 net income outlook to $3.1 billion-$3.3 billion from $3.9 billion-$4.1 billion and adjusted EBITDA guidance to $7.8 billion-$8.0 billion from $8.1 billion-$8.5
M impact | EQUITY | Oct 29, 2026, 02:02 PM UTC
Medical Properties Reports Third-Quarter 2026 Results
Medical Properties Trust reported third-quarter 2026 net income of $0.34 and normalized funds from operations of $0.11.
M impact | EQUITY | Oct 29, 2026, 02:01 PM UTC